Summary

Corona Remedies Limited reported a robust financial performance for Q4FY26 and the full fiscal year 2026, showcasing significant growth across key metrics. Revenue from operations grew by 20.2% year-over-year to ₹353.1 crore in Q4FY26 and by 17.3% to ₹1,403.2 crore for FY26. Profit After Tax (PAT) demonstrated even stronger growth, increasing by 43.7% in Q4FY26 to ₹45.3 crore and by 33.4% for FY26 to ₹199.4 crore, supported by notable PAT margin expansion. Managing Director & CEO, Mr. Nirav K. Mehta, affirmed FY26 as a strong year, highlighting the strategic focus on brand building, specialty segments, and portfolio expansion through acquisitions as key drivers positioning the company for sustainable future growth.

Key Highlights

1. 1

   Corona Remedies Limited reported revenue from operations of ₹353.1 crore for Q4FY26, marking a robust 20.2% year-over-year growth, and ₹1,403.2 crore for the full fiscal year 2026, representing a 17.3% increase.

2. 2

   Profit After Tax (PAT) for Q4FY26 surged by 43.7% to ₹45.3 crore, while the PAT for the entire FY26 grew by 33.4% to ₹199.4 crore.

3. 3

   PAT margin expanded significantly by 210 basis points to 12.8% in Q4FY26 and by 172 basis points to 14.2% for the full fiscal year 2026, driven by operating leverage and cost optimization.

4. 4

   The company strategically acquired WOKADINE, marking its entry into the substantial ₹648 crore Povidone Iodine market, with the acquisition fully funded through internal accruals.

5. 5

   Corona Remedies successfully relaunched key brands like Fostine R, Menodac, and Noklot, expanding its addressable market, and achieved the milestone of two brands surpassing ₹100 crore in MAT revenue by March 2026.

6. 6

   The company improved its market position to the 27th rank in India, advancing 5 spots in the last three years, and obtained EAEU-GMP certification to enter markets including Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.